Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up

MLA

Charles Chuah, et al. “Final Analysis of the Efficacy and Safety of Omacetaxine Mepesuccinate in Patients with Chronic- or Accelerated-Phase Chronic Myeloid Leukemia: Results with 24 Months of Follow-Up.” Cancer, vol. 121, Jan. 2015, pp. 1637–44. EBSCOhost, https://doi.org/10.1002/cncr.29240.

APA

Charles Chuah, Jeffrey H. Lipton, Elizabeth Li, Agnès Guerci-Bresler, Mauricette Michallet, Franck E. Nicolini, Andrzej Hellmann, Luke P. Akard, Delphine Rea, Mihaela Munteanu, Michele Baccarani, Krzysztof Warzocha, Meir Wetzler, Hagop M. Kantarjian, H. Jean Khoury, Jorge E. Cortes, Purvish M. Parikh, Raghunadharao Digumarti, & Laurence Legros. (2015). Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up. Cancer, 121, 1637–1644. https://doi.org/10.1002/cncr.29240

Chicago

Charles Chuah, Jeffrey H. Lipton, Elizabeth Li, Agnès Guerci-Bresler, Mauricette Michallet, Franck E. Nicolini, Andrzej Hellmann, et al. 2015. “Final Analysis of the Efficacy and Safety of Omacetaxine Mepesuccinate in Patients with Chronic- or Accelerated-Phase Chronic Myeloid Leukemia: Results with 24 Months of Follow-Up.” Cancer 121 (January): 1637–44. doi:10.1002/cncr.29240.